Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
14 nov. 2019 16h05 HE
|
Trevi Therapeutics
Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...
Trevi Therapeutics to Present at Stifel Healthcare Conference
13 nov. 2019 17h01 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments
12 août 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
13 juin 2019 16h09 HE
|
Trevi Therapeutics
Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis...
Trevi Therapeutics Announces Pricing of Initial Public Offering
07 mai 2019 13h22 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to...
Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results
08 août 2017 16h01 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. ...
Adamas to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8, 2017
01 août 2017 14h33 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August...
Adamas Appoints New Chief Financial Officer
28 juin 2017 09h00 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif, June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to...
Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology
12 juin 2017 16h01 HE
|
Adamas Pharmaceuticals, Inc.
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson’s Disease Patients with Levodopa-induced Dyskinesia -- --...
Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks
08 juin 2017 16h10 HE
|
Adamas Pharmaceuticals, Inc.
-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo -- -- New Drug Application...